Emergent BioSolutions Inc. - Q1 2011 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011. Emergent BioSolutions Inc. operates in two primary segments: Biodefense (focused on the FDA-approved anthrax vaccine BioThrax) and Biosciences (focused on vaccines and antibody therapies for infectious diseases, oncology, and autoimmune disorders). The company is heavily dependent on U.S. government contracts for its primary revenue stream.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $18.5 million | $46.8 million |
| Net Loss (Attributable to Emergent) | $(21.4) million | $2.5 million (Income) |
| Operating Loss | $(35.5) million | $3.2 million (Income) |
| Cash and Cash Equivalents | $136.9 million | $116.4 million |
| Total Debt Outstanding | $46.6 million | $50.0 million |
| Net Cash Used in Operating Activities | $(22.1) million | $17.4 million |
Note: All figures in millions unless otherwise noted. Margins are not applicable due to operating losses.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 60% year-over-year. Product sales plummeted 86% to $5.6 million (from $38.9 million) due to an 88% reduction in BioThrax doses delivered. This was caused by a manufacturing shutdown in late 2010, qualification of a second fill-finish manufacturer, and redeployment of testing capacity. Conversely, contracts and grants revenue increased 63% to $12.9 million, driven by new BARDA contracts and collaborations.
- Profitability Shift: The company swung from a net income of $2.5 million in Q1 2010 to a net loss of $21.4 million in Q1 2011. This was driven by the revenue drop and a 74% increase in Research and Development (R&D) expenses to $34.8 million.
- R&D Spending: R&D expenses rose significantly, with $13.9 million attributed to the Biosciences segment (including programs acquired from Trubion Pharmaceuticals) and $0.9 million to Biodefense programs.
- Balance Sheet: Cash decreased by $32.1 million during the quarter. Accounts receivable dropped significantly ($27.4 million) due to collections from the U.S. government, while inventory increased by $9.4 million due to shipment timing.
Guidance, Outlook, and Risks
- Contract Outlook: In April 2011 (subsequent to the period end), the company secured a contract modification to supply an additional 3.4 million doses of BioThrax valued at up to $101 million. The existing HHS contract expires in September 2011, and the company is in discussions for a multi-year procurement contract.
- Manufacturing: The company is qualifying Building 55 in Lansing, Michigan, for large-scale BioThrax manufacturing under a BARDA contract. It is also renovating a facility in Baltimore, Maryland.
- Key Risks:
- Government Dependence: Substantially all revenue is derived from U.S. government contracts. Future funding is subject to Congressional appropriations and political priorities.
- Manufacturing Complexity: BioThrax manufacturing is complex; reliance on a single fill-finish provider and specific animal strains for potency testing creates supply chain risks.
- Product Development: The Biosciences segment has not yet generated product sales. Success depends on clinical trial outcomes and regulatory approvals for candidates like TRU-016 (with Abbott) and SBI-087 (with Pfizer).
- Legal Proceedings: A class-action lawsuit regarding the Trubion acquisition settlement is pending final court approval. Patent oppositions against Bavarian Nordic regarding MVA technology are ongoing.
Investor Verification Checklist
- Contract Renewal Status: Verify the terms and likelihood of securing a new multi-year BioThrax procurement contract with HHS before the current agreement expires in September 2011.
- Manufacturing Capacity: Confirm the timeline for FDA qualification of Building 55 and the second fill-finish contract manufacturer to ensure future delivery capabilities.
- Biosciences Pipeline: Monitor clinical trial progress and funding status for key candidates (TRU-016, SBI-087) and the impact of the Trubion acquisition integration on R&D burn rates.
- Liquidity Runway: Assess whether current cash reserves ($136.9 million) and contract revenue are sufficient to fund operations and capital expenditures without additional financing, given the high R&D spend.
- Legal Resolution: Track the final court approval of the Trubion acquisition class-action settlement to ensure no unexpected liabilities arise.